COMMUNIQUÉS West-GlobeNewswire

ABLi Therapeutics to Present at the Citizens Life Sciences Conference
05/03/2026
ATLANTA and BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl [...]
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
05/03/2026
Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass [...]
CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent
05/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement issued by Sarborg Limited (“Sarborg”) regarding the [...]
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
05/03/2026
Agreement Combines Tenaya’s Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront [...]
Children’s Wisconsin and Xealth to Present Key Insights on Scalable Digital Patient Experience Programs at HIMSS26
05/03/2026
LAS VEGAS, March 05, 2026 (GLOBE NEWSWIRE) -- HIMSS— Xealth , the leading care orchestration platform for digital health, today announced that Xealth COO and Co-founder Aaron Sheedy will join Children’s Wisconsin Chief [...]
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
05/03/2026
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases [...]
ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference
05/03/2026
Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on 177 Lu-edotreotide arm vs. 14.7 months on everolimus arm Objective response rate (ORR) was higher across the [...]
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
05/03/2026
Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital, Dr. Mina [...]
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
05/03/2026
– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing [...]
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
05/03/2026
Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 [...]
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
05/03/2026
Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP earnings* of $0.24 [...]
HUTCHMED Reports 2025 Full Year Results and Business Updates
05/03/2026
— Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth — — $457 million net income, driven by profitable core operations and non-core disposal — — Rapidly progressing [...]
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
05/03/2026
Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement [...]
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
05/03/2026
Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 points on top of Standard of Care (“SoC”) at 6 weeks Durable effects sustained through at [...]
Nephros Schedules Fourth Quarter 2025 Financial Results Conference Call
05/03/2026
SOUTH ORANGE, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will [...]
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
05/03/2026
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE [...]
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
05/03/2026
Achieved Q4 2025 PEMGARDA ® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter 2025 year-end cash and cash equivalents of $226.7 million after [...]
Kraig Biocraft Laboratories Targets New Industrial and Defense Biomaterials as "Project Atlas" Hits Major Milestone
05/03/2026
ANN ARBOR, Mich., March 05, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a major [...]
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
05/03/2026
Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 – Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter of 2026 – AUSTIN, [...]

Pages